Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumabs - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agents for dermatitis, excluding corticosteroids - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin lispro - cukura diabēts - cukura diabēts - Ārstējot pieaugušos un bērnus ar cukura diabētu, kuriem insulīnam nepieciešama normāla glikozes homeostāzes uzturēšana. insulin lispro sanofi ir indicēts arī cukura diabēta sākotnējai stabilizācijai.

Latvia - Tiếng Latvia - Zāļu valsts aģentūra

engelhard arzneimittel gmbh & co.kg, germany - vijīgās efejas lapu sausais ekstrakts - pilieni iekšķīgai lietošanai, šķīdums - 20 mg/ml

Latvia - Tiếng Latvia - Zāļu valsts aģentūra

sanofi winthrop industrie, france - zopiklons - apvalkotā tablete - 7,5 mg

Latvia - Tiếng Latvia - Zāļu valsts aģentūra

engelhard arzneimittel gmbh & co.kg, germany - vijīgās efejas lapu sausais ekstrakts - sīrups - 7 mg/ml

Latvia - Tiếng Latvia - Zāļu valsts aģentūra

upsa sas, france - paracetamolum, skābes ascorbicum - putojošā tablete - 330 mg/200 mg

Latvia - Tiếng Latvia - Zāļu valsts aģentūra

sanofi winthrop industrie, france - zolpidēma tartrāts - apvalkotā tablete - 10 mg

Latvia - Tiếng Latvia - Zāļu valsts aģentūra

sanofi winthrop industrie, france - alfuzosīna hidrohlorīds - ilgstošās darbības tablete - 10 mg

Latvia - Tiếng Latvia - Zāļu valsts aģentūra

upsa sas, france - paracetamols - supozitorijs - 80 mg

Latvia - Tiếng Latvia - Zāļu valsts aģentūra

upsa sas, france - paracetamols - supozitorijs - 150 mg